General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives $15.86 Average PT from Analysts | news.google.com • |
Raymond James & Associates Has $71000 Stock Position in AbCellera Biologics Inc. (NASDAQ:ABCL) | news.google.com • |
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Bought by Handelsbanken Fonder AB | news.google.com • |
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Acquired by Signaturefd LLC | news.google.com • |
AbCellera Biologics (NASDAQ:ABCL) Trading Up 7% | news.google.com • |
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Tops Revenue Estimates | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-07 | 2024-03 | -0.16 | N/A | N/A | N/A |
2024-02-20 | 2023-12 | -0.14 | -0.17 | -0.03 | -21.43% |
2023-11-02 | 2023-09 | -0.14 | -0.1 | 0.04 | 28.57% |
2023-11-02 | 2023-09 | -0.14 | N/A | N/A | N/A |
2023-08-03 | 2023-06 | -0.13 | -0.11 | 0.02 | 15.38% |
2023-08-03 | 2023-06 | -0.13 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-30 | Benchmark | Upgrade | Buy | Buy |
2023-08-03 | Goldman Sachs | Upgrade | Buy | Buy |
2023-05-04 | Credit Suisse | Upgrade | Outperform | |
2023-02-27 | Cowen & Co. | Upgrade | Outperform | |
2023-02-21 | BMO Capital | Upgrade | Outperform | |
2023-02-21 | Credit Suisse | Upgrade | Outperform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-05-25 | BOOTH ANDREW | Chief Financial Officer | 283.96K | Purchase |
2021-08-31 | FALCONER ESTER | Chief Technology Officer | 875.00K | Conversion of Exercise of derivative security |
2021-08-31 | HAMER JOHN | Director | 14.73M | Sale |
2024-02-25 | HANSEN CARL L.G. | Chief Executive Officer | 56.53M | Conversion of Exercise of derivative security |
2023-09-21 | HAYDEN MICHAEL REUBEN | Director | 0.00 | Purchase |
2023-09-11 | LECAULT VERONIQUE | Chief Operating Officer | 9.53M | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Baillie Gifford and Company | 26.36M | 170.32M | 9.11% |
2023-06-29 | Baker Brothers Advisors, LLC | 16.45M | 106.27M | 5.69% |
2023-06-29 | Voya Investment Management LLC | 10.62M | 68.63M | 3.67% |
2023-06-29 | Capital World Investors | 8.42M | 54.40M | 2.91% |
2023-06-29 | Credit Suisse Ag/ | 4.57M | 29.55M | 1.58% |
2023-06-29 | Orbimed Advisors LLC. | 4.18M | 27.01M | 1.44% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Smallcap World Fund | 5.48M | 35.40M | 1.89% |
2023-06-29 | American Funds Insurance Ser-Asset Allocation Fund | 2.87M | 18.55M | 0.99% |
2023-08-30 | iShares NASDAQ Biotechnology ETF | 1.39M | 7.58M | 0.48% |
2023-06-29 | Avantis U.S. Small Cap Value Fund | 913.07K | 5.90M | 0.32% |
2023-06-29 | Baillie Gifford International Alpha Fund | 835.46K | 5.40M | 0.29% |
2023-07-30 | Old Westbury Small & Mid Cap Strategies Fund | 841.88K | 6.51M | 0.29% |
Watch out for $SRNE
Sorrento therapeutics is making a better product under darpa contract!
DARPA didn’t want to give up all there secrets
The Google of Pharm
$fuxk
$12 not ️️️
holy shit
$abcl 10 not too long
abcl 10 next week
$10 not far